Focus Partners Advisor Solutions LLC Reduces Stock Position in Bristol Myers Squibb Company $BMY

Focus Partners Advisor Solutions LLC cut its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 21.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,478 shares of the biopharmaceutical company’s stock after selling 25,929 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Bristol Myers Squibb were worth $5,559,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in BMY. Brighton Jones LLC raised its position in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC increased its stake in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank raised its holdings in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares in the last quarter. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $221,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $405,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $64.71 on Tuesday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.10. The stock has a market capitalization of $132.18 billion, a price-to-earnings ratio of 14.25, a PEG ratio of 0.17 and a beta of 0.22. The company has a 50-day simple moving average of $59.75 and a 200-day simple moving average of $59.06. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the company posted $1.46 earnings per share. The business’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of recent analyst reports. Roth Capital began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 target price on the stock. Citigroup reissued a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Raymond James Financial initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.